Placebo News and Research

RSS

Taiho Oncology presents TAS-102 Phase III RECOURSE trial results in mCRC patients

Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), announced today detailed findings from its global Phase III RECOURSE trial of TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an oral combination anticancer drug.

28 Jun 2014

Researchers identify two classes of anti-depressants that reduce symptoms of depression

Depression is common in cancer, up to half of all patients facing the disease experience depressive symptoms, ranging from mild to severe. When depression co-exists with cancer, patients may be at an increased risk of death from cancer and from suicide.

28 Jun 2014

Afrezza gets FDA approval to improve glycemic control in adults with diabetes mellitus

The U.S. Food and Drug Administration today approved Afrezza (insulin human) Inhalation Powder, a rapid-acting inhaled insulin to improve glycemic control in adults with diabetes mellitus. Afrezza is a rapid-acting inhaled insulin that is administered at the beginning of each meal, or within 20 minutes after starting a meal.

28 Jun 2014

Vertex receives positive opinion from European CHMP for approval of KALYDECO for cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced that the European Committee for Medicinal Products for Human Use has issued a positive opinion recommending the approval of KALYDECO (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight non-G551D gating mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

28 Jun 2014

Dosing commences in Essentialis’ DCCR clinical study in obese Prader-Willi syndrome patients

Essentialis announced today the dosing of the first patient in clinical study PC025, which is designed to evaluate the safety and efficacy of diazoxide choline controlled release tablets (DCCR) in obese Prader-Willi syndrome patients.

27 Jun 2014

Researchers perform systematic review to identify best treatments for cancer-related depression

27 Jun 2014

ASPIRE completes patient enrollment in Phase III trial of vaginal ring for HIV prevention

ASPIRE, one of two Phase III trials of a promising method for preventing HIV in women - a vaginal ring worn for a month at a time - has completed enrollment of participants, with 2,629 women from 15 clinical research sites in Malawi, South Africa, Uganda and Zimbabwe now taking part in the study.

27 Jun 2014

Henry Ford launches clinical trial for treatment of tinnitus caused by noise trauma

Henry Ford Health System has launched a clinical trial to investigate a new drug for the treatment of tinnitus, a chronic ringing of the head or ears that affects more than 600 million people worldwide.

25 Jun 2014

Alcoholic liver disease: an interview with Dr Vinood Patel, University of Westminster

Alcoholic liver disease (ALD) is one of the leading causes of death worldwide and also in the UK. As its name indicates this disease arises due to consuming excessive amounts of alcohol (80 g/day) over an extended period, normally 10-20 years.

24 Jun 2014

Trevena's Phase 1b data for TRV130 published in the journal Pain

Trevena, Inc., a clinical stage biopharmaceutical company and the leader in the discovery of G protein coupled receptor (GPCR) biased ligands, today announced the publication of its Phase 1b data for TRV130 in the journal Pain.

24 Jun 2014

Gelesis100 capsule leads to greater weight loss in overweight, obese individuals

A new "smart pill" called Gelesis100 safely leads to greater weight loss in overweight and obese individuals compared with those who receive an active comparator/placebo capsule, while all subjects have similar diet and exercise instructions, an international multicenter study finds.

24 Jun 2014

Forest Laboratories reports positive results from three Phase III trials of vilazodone for GAD treatment

Forest Laboratories, Inc. today announced positive topline results from three Phase III trials evaluating the efficacy, safety and tolerability of vilazodone in adult patients with generalized anxiety disorder (GAD).

24 Jun 2014

Researchers develop GI microbiome modulators to treat prediabetes and diabetes

In adults with prediabetes, a new drug that alters microbial populations and their environment in the gastrointestinal (GI) tract improves glucose tolerance-the body's response to consuming carbohydrates- after four weeks of treatment and without a change in diet.

24 Jun 2014

Testosterone therapy may improve aerobic capacity in aging men

Testosterone replacement therapy may help older men who have limited mobility and low testosterone improve their aerobic capacity and lessen its decline with age, new research finds.

24 Jun 2014

XenoPort initiates XP23829 Phase 2 clinical trial in patients with psoriasis

XenoPort, Inc. announced today that it has initiated a Phase 2 clinical trial of XP23829, its proprietary investigational next-generation fumaric acid product candidate. The trial is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of XP23829 as a potential treatment of patients with moderate-to-severe chronic plaque-type psoriasis.

23 Jun 2014

Empagliflozin lowers blood pressure in patients with Type 2 diabetes and hypertension

An investigational drug to treat Type 2 diabetes, empagliflozin, lowers blood pressure in patients with Type 2 diabetes and hypertension (high blood pressure), a new study finds.

23 Jun 2014

Treatment with diabetes drug liraglutide improves cardiovascular risk factors

Treatment with the diabetes drug liraglutide, in combination with diet and exercise, led to a significant reduction in weight and improved a number of cardiovascular risk factors, including high blood pressure and high cholesterol, according to a multicenter study.

23 Jun 2014

Denosumab increases bone density for postmenopausal women with osteoporosis

Postmenopausal women with osteoporosis who take denosumab long-term have increased bone density, sustained low rate of fractures, and a favorable benefit/risk profile, a new multinational study finds.

23 Jun 2014

African American women respond differently to anti-inflammatory effect of aspirin than white women

African American women respond differently to the anti-inflammatory effect of aspirin than do white American women, new research finds.

23 Jun 2014

Aradigm begins Pulmaquin Phase III study for treatment of non-CF BE

Aradigm Corporation ("Aradigm" or the "Company") today announced the dosing of the first patient in the ORBIT-4 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) Phase III pivotal clinical trial of Aradigm's proprietary formulation of inhaled ciprofloxacin (Pulmaquin®) for the treatment of non-cystic fibrosis bronchiectasis (non-CF BE).

23 Jun 2014

Placebo News and Research

Taiho Oncology presents TAS-102 Phase III RECOURSE trial results in mCRC patients

Researchers identify two classes of anti-depressants that reduce symptoms of depression

Afrezza gets FDA approval to improve glycemic control in adults with diabetes mellitus

Vertex receives positive opinion from European CHMP for approval of KALYDECO for cystic fibrosis

Dosing commences in Essentialis’ DCCR clinical study in obese Prader-Willi syndrome patients

Researchers perform systematic review to identify best treatments for cancer-related depression

ASPIRE completes patient enrollment in Phase III trial of vaginal ring for HIV prevention

Henry Ford launches clinical trial for treatment of tinnitus caused by noise trauma

Alcoholic liver disease: an interview with Dr Vinood Patel, University of Westminster

Trevena's Phase 1b data for TRV130 published in the journal Pain

Gelesis100 capsule leads to greater weight loss in overweight, obese individuals

Forest Laboratories reports positive results from three Phase III trials of vilazodone for GAD treatment

Researchers develop GI microbiome modulators to treat prediabetes and diabetes

Testosterone therapy may improve aerobic capacity in aging men

XenoPort initiates XP23829 Phase 2 clinical trial in patients with psoriasis

Empagliflozin lowers blood pressure in patients with Type 2 diabetes and hypertension

Treatment with diabetes drug liraglutide improves cardiovascular risk factors

Denosumab increases bone density for postmenopausal women with osteoporosis

African American women respond differently to anti-inflammatory effect of aspirin than white women

Aradigm begins Pulmaquin Phase III study for treatment of non-CF BE

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News